Cyteir Therapeutics, Inc.
cyteir.comNo Longer Reporting
The company has not filed an annual or quarterly report since its Q3 FY2023 10-Q, filed Nov 6, 2023. Its latest SEC filing is a 15-12G from Mar 29, 2024.
10-Q for Q3 FY2023, filed Nov 6, 2023
The sections below describe the company as of the FY2022 annual report.
What Did They Do?
Develops an oral experimental cancer drug for patients with ovarian cancer and other solid tumors.
10-K for FY2022, filed Mar 23, 2023
How Were They Changing?
- Net income
-
Sources
10-Q for Q3 FY2023, filed Nov 6, 2023
−$3.5MView ↗
- ▼ −68% (Loss)
- vs −$11M in Q3 FY2022
-
Mar 20, 2024
Filed dissolution certificate and set a date for future distributions
Cyteir estimated available cash distributions of $3.10 to $3.16 per share.
Sources
8-K, filed Mar 20, 2024
The Company currently estimates that the aggregate amount of cash that will be available for the Common Stock Liquidation Distributions…View ↗
-
Mar 7, 2024
Notified Nasdaq of plans to delist its common stock
The planned delisting is part of the company’s liquidation and dissolution.
Sources
8-K, filed Mar 7, 2024
On March 7, 2024, Cyteir Therapeutics, Inc. (the “Company”) delivered formal notice to The Nasdaq Stock Market that the Company intends to…View ↗
-
Jun 30, 2023
Discontinued CYT-0851 development and planned company dissolution
The company said clinical results did not meet its criteria to advance the program.
Sources
8-K, filed Jun 30, 2023
On June 30, 2023, Cyteir Therapeutics, Inc. (“Cyteir” or the "Company") announced the discontinuation of CYT-0851, its investigational…View ↗
Who Did They Compete With?
Competes with Sutro, Aravive, Mersana, Mereo/OncXerna, Esai/BMS, Verastem, Acrivon, and Zentalis
10-K for FY2022, filed Mar 23, 2023Other therapies in development, such as luvelta (Sutro), batiraxcept (Aravive), Upifitamab Rilsodotin (Mersana), navicixizumab…View ↗
Loading...
